Compare Cytokinetics Inc (CYTK) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs TORM plc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while TORM plc trades at $39.94 (market cap $4.12B). The key difference: Cytokinetics Inc is far larger — about 2.1× TORM plc's market cap, and TORM plc pays a 11.03% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and TORM plc for 23 Days on average.
| CYTK | TRMD | |
|---|---|---|
Market Cap | $8.62B | $4.12B |
Volume | 2,594,626 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $87.26 | $41.05 |
52-Week Low | $54.76 | $19.39 |
Typical Hold Time | 19 Days | 23 Days |
Enterprise Value | $8.72B | $4.83B |
Dividend Yield | — | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
TRMD trades at $40.06, up 2.93% today, with strong technical momentum showing bullish moving averages. The company demonstrates robust fundamentals with a P/E of 6.59, net income margin of 35.52%, and ROE of 26.84%. Recent earnings showed mixed results with Q2 2026 missing expectations, but 2026 projections indicate significant revenue growth to $1.8B. Analyst consensus is unanimously bullish with 100% buy ratings.
The outlook remains positive given strong profitability metrics and institutional interest, though risks include spot rate volatility in the tanker market and recent insider selling. Current valuation appears attractive relative to earnings power, but investors should monitor Q3 2026 earnings results against the $1.54 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
